Aura biosciences, inc.AURA.US Overview

US StockHealthcare

(No presentation for AURA)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

AURA Overall Performance

AURA AI Analysis & Strategy

AURA Recent Performance

2.81%

Aura biosciences, inc.

0.81%

Avg of Sector

-1.14%

S&P500

AURA PowerScanner

AURA Key Information

AURA Valuation Metrics

AURA Earnings Table

AURA Profile

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.